Avacta, based at the York Biocentre, develops detection and analysis technology aimed at the defence, security, pharmaceutical and clinical diagnostics markets.
The company’s current research is aimed at formulating methods of analysing liquids using laser spectroscopy. The goal of the Dstl contract is to enable the rapid identification of liquids in the field.
Professor Alastair Smith, Avacta’s chief executive, said: ‘We are delighted with the new contract for the development of a robust, prototype device. Laser detection and diagnostic devices are a key part of Avacta’s portfolio of technologies and this contract with the MoD is an important step for the company.’